fda sued over tirzepatide Says Compounded Must Exit the Market FDA Reversal on Knockoff GLP-1

The difference between oral tirzepatide and its injectable counterpart, as highlighted in discussions comparing "tirzepatide oral vs injection," underscores the lack of evidence supporting comparable effectiveness

and Robertson Therapeutic Development Fund/Kellen Womens Entrepreneurship Fund (TDF/WEF)

We are not yet offering AOD 9604 to patients

reported in a propensity score-matched population-based cohort analysis that GLP-1 receptor agonist use in patients with MASLD and type 2 diabetes was associated with a lower risk of HCC (aHR: 0.55, 95%CI: 0.44-0.69) and all-cause mortality (aHR: 0.62, 95%CI: 0.55-0.71) [59]